Psychotic Decompensation During Nalmefene Treatment in a Patient With Schizoaffective Disorder - Université Toulouse III - Paul Sabatier - Toulouse INP Accéder directement au contenu
Article Dans Une Revue Journal of Dual Diagnosis Année : 2019

Psychotic Decompensation During Nalmefene Treatment in a Patient With Schizoaffective Disorder

Résumé

Objective: Nalmefene is a kappa-opioid receptor agonist/antagonist which is currently prescribed to reduce heavy drinking days. Adverse events (AEs) have previously been described in trials, but these trials excluded patients with psychiatric comorbidities. This is important as psychiatric disorders are frequently associated with alcohol use disorders; therefore, the specific AEs in this population should be investigated. Methods: Here, we describe the case of a patient with diagnosed alcohol use disorder and schizoaffective disorder who received treatment with nalmefene. Results: The patient showed decompensation of psychotic symptoms after two doses of medication, consisting of auditory hallucinations, delusions, and ideas of persecution. The symptoms improved two days after treatment discontinuation. Conclusions: This case indicates that the AEs of nalmefene should be specifically investigated in patients with psychiatric disorders.
Fichier non déposé

Dates et versions

hal-03605429 , version 1 (11-03-2022)

Identifiants

Citer

Juliette Salles, Camille Ponté, Laurent Schmitt. Psychotic Decompensation During Nalmefene Treatment in a Patient With Schizoaffective Disorder: A Case Report. Journal of Dual Diagnosis, 2019, 15 (2), pp.118-121. ⟨10.1080/15504263.2019.1574367⟩. ⟨hal-03605429⟩
7 Consultations
0 Téléchargements

Altmetric

Partager

Gmail Mastodon Facebook X LinkedIn More